Dawn L. Hershman, MD, MS, Columbia University Medical Center, discusses the results of a recent study that found diabetes, age, and certain treatment regimens are contributing factors to developing chemotherapy-induced peripheral neuropathy (CIPN).
The study, which examined more than 1400 patients over the age of 65, reports that CIPN rates increase with age, and patients with diabetes treated with a taxane had nearly a twofold risk of developing CIPN, as were those treated with paclitaxel versus docetaxel.
Conversely, patients who had an autoimmune disease actually showed lower rates of CIPN, which, Hershman notes, raises intriguing questions for further study.
Nursing Perspectives on Managing Toxicities With ADCs in Metastatic Gastric and Breast Cancers
September 1st 2022In this episode of "The Vitals," Sarah Donahue, MPH, NP, AOCNP; Jamie Carroll, APRN, CNP, MSN; Theresa Wicklin Gillespie, PhD, MA, RN, FAAN; and Elizabeth Prechtel-Dunphy, DNP, RN, ANP-BC, AOCN, exchange clinical pearls for treating patients receiving antibody-drug conjugates.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Side Effect Education Critical for Patients With Cervical Cancer Treated With Pembrolizumab
January 22nd 2024With pembrolizumab plus chemoradiotherapy now approved by the FDA for patients with advanced cervical cancer, one expert explained the importance of “making sure that patients know what to look for and what to report.”